中国组织工程研究 ›› 2016, Vol. 20 ›› Issue (45): 6788-6794.doi: 10.3969/j.issn.2095-4344.2016.45.015

• 干细胞移植 stem cell transplantation • 上一篇    下一篇

人羊膜间充质干细胞移植修复肝脏缺血-再灌注损伤

王新党1,张建军2,叶  奎3   

  1. 1石家庄市鹿泉区铜冶镇中心卫生院普外科,河北省石家庄市  050200;天津市第四中心医院,2神经外科,3肝胆外科,天津市  300143
  • 修回日期:2016-09-28 出版日期:2016-11-04 发布日期:2016-11-04
  • 作者简介:王新党,男,1974年生,河北省石家庄市人,汉族,2008年河北医科大学毕业,主治医师,主要从事普外科研究。

Human amniotic mesenchymal stem cell transplantation for the repair of liver ischemia-reperfusion injury

Wang Xin-dang1, Zhang Jian-jun2, Ye Kui3   

  1. 1Department of General Surgery, Central Health Center of Tongye County, Shijiazhuang 050200, Hebei Province, China; 2Department of Neurosurgery, 3Department of Hepatobiliary Surgery, Tianjin Fourth Central Hospital, Tianjin 300143, China
  • Revised:2016-09-28 Online:2016-11-04 Published:2016-11-04
  • About author:Wang Xin-dang, Attending physician, Department of General Surgery, Central Health Center of Tongye County, Shijiazhuang 050200, Hebei Province, China

摘要:

文章快速阅读:

文题释义:
人羊膜间充质干细胞:
经体外诱导培养后可分化成神经细胞、胰腺细胞、心肌细胞等来自3个胚层的细胞。而目前,国内外研究也表明人羊膜间充质干细胞可以分化为肝细胞样细胞,提示肝损伤后进行人羊膜间充质干细胞移植为临床肝病治疗提供可能。
肝脏缺血-再灌注损伤:肝损害的基础是发生肝纤维化,肝星状细胞激活是肝纤维化发生的中心环节,肝星状细胞活化后细胞表型改变,特征性表达α-平滑肌肌动蛋白,导致肝纤维化;其表达量的高低与肝星状细胞活化、肝细胞纤维化程度均呈正相关,所以,α-平滑肌蛋白表达量的检测,可较好反映肝损害程度。

 

摘要
背景:
国内外研究表明,人羊膜间充质干细胞可分化为肝细胞样细胞,提示肝损伤后进行人羊膜间充质干细胞移植为临床肝病治疗提供可能。
目的:观察人羊膜间充质干细胞移植对大鼠肝脏缺血-再灌注损伤的修复作用。
方法:将60只SD大鼠随机分为3组,干细胞移植组、模型组建立大鼠肝脏缺血-再灌注损伤模型,造模后1 h,干细胞移植组于尾静脉注射人羊膜间充质干细胞0.5 mL(106个),模型组于尾静脉注射L-DMEM 0.5 mL,正常对照组于尾静脉注射生理盐水0.5 mL。移植后1,2,3周,进行肝功能、肝组织形态学、RT-PCR法及Western blot检测。
结果与结论:①肝功能:与正常对照组比较,模型组移植后不同时间点的门冬氨酸转移酶、丙氨酸转移酶和丙二醛水平明显升高(P < 0.05);与模型组比较,干细胞移植组移植后不同时间点的门冬氨酸转移酶、丙氨酸转移酶和丙二醛水平明显降低(P < 0.05);②肝组织形态:移植后2周,模型组肝细胞变性、坏死及纤维化程度严重,干细胞移植组肝细胞变性、坏死及纤维化程度较模型组明显减轻;③RT-PCR法及Western blot检测:移植后2周,与模型组比较,干细胞移植组肝组织肝细胞生长因子水平明显升高(P < 0.05),α-平滑肌蛋白明显下降(P < 0.05);④结果表明:人羊膜间充质干细胞移植能有效改善大鼠受损的肝功能,其可能通过调节肝细胞生长因子及α-平滑肌蛋白在肝脏中的表达水平,进而发挥促进大鼠肝脏缺血-再灌注损伤修复的作用。

 

 

关键词: 干细胞, 移植, 人羊膜间充质干细胞, 大鼠, 肝脏, 缺血-再灌注损伤, 修复, 肝损伤, 肝细胞生长因子, α-平滑肌蛋白

Abstract:

BACKGROUND: Studies have shown that human amniotic mesenchymal stem cells can differentiate into hepatocyte-like cells, suggesting that human amniotic mesenchymal stem cell transplantation provides a new potential for the clinical treatment of liver diseases.
OBJECTIVE: To observe the effect of human amniotic mesenchymal stem cell transplantation on the repair of liver ischemia-reperfusion injury repair.
METHODS: Sixty Sprague-Dawley rats were randomized into stem cell transplantation, model and control groups. Animal models of liver ischemia-reperfusion injury were made in the rats in the stem cell transplantation and model groups. One hour after modeling, rats in the stem cell transplantation were given injection of human amniotic mesenchymal stem cells (0.5 mL, 106 cells) via the tail vein, while rats in the model and control group were given L-DMEM (0.5 mL) or normal saline (0.5 mL), respectively. Liver function and liver morphology were detected at 1, 2, 3 weeks after transplantation. Meanwhile, RT-PCR detection and western blot assay were also conducted.
RESULTS AND CONCLUSION: (1) Liver function: Compared with the control group, levels of aspartate aminotransferase, alanine aminotransferase and malondialdehyde were significantly increased in the model group at different time points after transplantation (P < 0.05), while a significant reduction in the levels of these three indicators was found after cell transplantation as compared with the model group (P < 0.05). (2) Liver morphology: 2 weeks after transplantation, rats in the model group exhibited hepatocyte degeneration and necrosis, and severe fibrosis, but these changes were remarkably alleviated in the stem cell transplantation group. (3) PT-PCR and western blot detection: 2 weeks after transplantation, a significantly higher level of hepatocyte growth factor in the liver tissue and a lower level of α-smooth muscle protein were found in the stem cell transplantation group compared with the model group (P < 0.05). All these experimental findings indicate that human amniotic mesenchymal stem cell transplantation can improve impaired liver function in rats, possibly through regulating hepatocyte growth factor and α-smooth muscle protein expression levels in the liver, and thereby promotes the repair of liver ischemia-reperfusion injury.

 

 

Key words: Stem Cells, Mesenchymal Stem Cell Transplantation, Reperfusion Injury, Tissue Engineering

中图分类号: